Replimune reports fiscal 2026 results and FDA accepts BLA for RP1.

Replimune announced fiscal 2026 financial results and confirmed the FDA accepted its resubmission of the BLA for RP1 in combination with nivolumab for advanced melanoma with a goal date set for August 2026. This regulatory milestone, combined with strong clinical data presentations, supports the company's progress in securing approval for its oncolytic immunotherapy portfolio.